

## In Vivo Targeting of Hydrogen Peroxide by Activatable Cell-Penetrating Peptides

Roy Weinstein,<sup>†</sup> Elamprakash N. Savariar,<sup>†</sup> Csilla N. Felsen,<sup>†</sup> and Roger Y. Tsien<sup>\*,†,‡,§</sup><sup>†</sup>Department of Pharmacology, <sup>‡</sup>Department of Chemistry and Biochemistry, and <sup>§</sup>Howard Hughes Medical Institute, University of California San Diego, La Jolla, California 92093, United States

## Supporting Information


**ABSTRACT:** A hydrogen peroxide (H<sub>2</sub>O<sub>2</sub>)-activated cell-penetrating peptide was developed through incorporation of a boronic acid-containing cleavable linker between polycationic cell-penetrating peptide and polyanionic fragments. Fluorescence labeling of the two ends of the molecule enabled monitoring its reaction with H<sub>2</sub>O<sub>2</sub> through release of the highly adhesive cell-penetrating peptide and disruption of fluorescence resonance energy transfer. The H<sub>2</sub>O<sub>2</sub> sensor selectively reacts with endogenous H<sub>2</sub>O<sub>2</sub> in cell culture to monitor the oxidative burst of promyelocytes and in vivo to image lung inflammation. Targeting H<sub>2</sub>O<sub>2</sub> has potential applications in imaging and therapy of diseases related to oxidative stress.

Hydrogen peroxide (H<sub>2</sub>O<sub>2</sub>) is a reactive oxygen species (ROS) endogenously produced in living organisms. A growing body of evidence suggests that H<sub>2</sub>O<sub>2</sub> plays an active role in the regulation of various physiological processes.<sup>1,2</sup> Nevertheless, its overabundance results in oxidative stress that can lead to extensive cellular damage. Indeed, high levels of H<sub>2</sub>O<sub>2</sub> have been implicated in many pathological conditions including diabetes,<sup>3</sup> cardiovascular diseases,<sup>4,5</sup> neurodegenerative disorders,<sup>6</sup> and cancer.<sup>7</sup> Consequently, there is increased interest in the role of H<sub>2</sub>O<sub>2</sub> in normal and pathological conditions, as well as in its potential as a target in directed therapeutics delivery for oxidative stress related diseases. Traditionally, these objectives are pursued separately, through the development of dedicated molecular imaging probes<sup>8–11</sup> or drug delivery vehicles.<sup>12–14</sup> Current H<sub>2</sub>O<sub>2</sub> imaging agents that are in vivo compatible can only be applied to transgenic animals<sup>8,9</sup> or through localized administration,<sup>10,11</sup> while drug delivery vehicles aimed at H<sub>2</sub>O<sub>2</sub> require its presence at supranatural concentrations to achieve sufficient activation.<sup>12,13</sup> Therefore, progress could be made toward both objectives by developing molecular targeting agents that respond to physiological levels of H<sub>2</sub>O<sub>2</sub> in intact animals, and that could be harnessed with interchangeable cargo according to need.

An activatable cell-penetrating peptide (ACPP) uses a generic targeting mechanism based on selective and local unleashing of a cell-penetrating peptide (CPP).<sup>15</sup> It is a hairpin shaped molecule consisting of a polycationic CPP (D-Arg<sub>9</sub>) and an inhibitory polyanion (D-Glu<sub>9</sub>) connected through a cleavable linker. When intact, the polyanion neutralizes the polycation and largely masks the adhesiveness of the CPP. Extracellular

cleavage of the linker enables dissociation of the inhibitory polyanion from the CPP, releasing the CPP and associated cargo to adhere to and then penetrate into nearby cells. Through appropriate design of linkers, ACPPs have been directed toward extracellular enzymes such as matrix metalloproteinases,<sup>16</sup> elastases<sup>17</sup> and thrombin,<sup>18</sup> enabling in vivo detection of their spatially localized enzymatic activity by various imaging modalities. Thus, ACPPs are broadly applicable tools for concentrating cargo of interest at the site of its activation.

Here, we report the development of H<sub>2</sub>O<sub>2</sub> targeting agents based on ACPPs and demonstrate their ability to selectively image endogenous levels of H<sub>2</sub>O<sub>2</sub> in live cells and in vivo. We envisioned making an ACPP reactive toward H<sub>2</sub>O<sub>2</sub> by incorporation of 4-boronic mandelic acid as a keystone in its linker architecture (Figure 1A). The reaction of a phenylboronic acid with H<sub>2</sub>O<sub>2</sub> to form a phenol<sup>19–22</sup> has been extensively utilized to generate a wide range of small-molecule sensors for H<sub>2</sub>O<sub>2</sub>.<sup>23</sup>



**Figure 1.** Schematic illustration of H<sub>2</sub>O<sub>2</sub>-ACPP structure and its H<sub>2</sub>O<sub>2</sub>-triggered fragmentation process. (A) Fluorescence labeling of H<sub>2</sub>O<sub>2</sub>-ACPP peptide domains enables visualization of its cleavage through FRET disruption. Shown are the fluorescence emissions of (B) ACPP 1 and (C) ACPP 2 (1 μM each) before (purple) and 20 min after (green) reaction with H<sub>2</sub>O<sub>2</sub> (2 mM).

Received: November 12, 2013

Published: December 30, 2013


In our design, oxidation of the boronic acid by  $\text{H}_2\text{O}_2$  will form a phenolate that will subsequently undergo a spontaneous 1,6-elimination, resulting in fragmentation of the ACPP and release of the CPP domain. Visualization of the ACPP's reaction with  $\text{H}_2\text{O}_2$  could be facilitated by fluorescent labeling of both of its peptide domains. The close proximity enforced by the hairpin structure should lead to fluorescence resonance energy transfer (FRET), which would be disrupted by  $\text{H}_2\text{O}_2$ -mediated cleavage.

In line with the design presented in Figure 1A, ACPP 1 (Figure S1, Supporting Information (SI)) was prepared through a combination of in-solution and solid-phase synthesis (Schemes S1 and S2 (SI)). The polycationic and polyanionic domains of 1 were labeled with fluorescein (donor) and Cy5 (acceptor), respectively. When intact, ACPP 1 produces strong FRET, as evident by low emission from the donor (fluorescein,  $\sim 524$  nm) and strong re-emission from the acceptor (Cy5,  $\sim 670$  nm) (Figure 1B). Cleavage of the ACPP by  $\text{H}_2\text{O}_2$  leads to disruption of the FRET, which could be visualized through the increase in donor emission ( $\sim 6$ -fold) and decrease in the acceptor re-emission ( $\sim 7$ -fold). The combined  $\sim 40$ -fold ratio change is comparable with our previously reported FRET-ACPPs<sup>24</sup> and should provide a sufficient dynamic range to differentiate between  $\text{H}_2\text{O}_2$  levels. To test whether other donor/acceptor pairs are permissible in this design, we synthesized ACPP 2 (Figure S1 and Scheme S3 (SI)), where fluorescein and Cy5 were replaced with Alexa488 and Alexa594, respectively. Similar to ACPP 1, ACPP 2 showed efficient FRET that was disrupted in the presence of  $\text{H}_2\text{O}_2$  (Figure 1C).

Under normal physiological conditions,  $\text{H}_2\text{O}_2$ , although diffusible, forms a concentration gradient across cellular membranes,<sup>25,26</sup> with an intracellular concentration estimated at  $0.5\text{--}7 \times 10^{-7}$  M<sup>27,28</sup> and an extracellular concentration that is  $\sim 10$ -fold higher.<sup>29</sup> In pathological conditions, local extracellular concentrations of  $\text{H}_2\text{O}_2$  are additionally elevated to as high as  $10\text{--}50$   $\mu\text{M}$ .<sup>30–35</sup> Therefore, to effectively target extracellular  $\text{H}_2\text{O}_2$ , a sensitivity level in the low micromolar range is required. To determine its lowest detection limit, ACPP 1 ( $1$   $\mu\text{M}$ ) was incubated with increasing concentration of  $\text{H}_2\text{O}_2$  ( $0\text{--}250$   $\mu\text{M}$ ) and fluorescence emissions at 524 vs 672 nm ( $\lambda_{\text{ex}} = 488$  nm) were monitored over 20 min. The FRET ratio change ( $R/R_0$ ) was calculated by dividing the ratio of 524/672 nm emissions at each time-point ( $R$ ) by the ratio before  $\text{H}_2\text{O}_2$  addition ( $R_0$ ). This assay established a linear dependence of ACPP 1's FRET ratio change on  $\text{H}_2\text{O}_2$  concentration ( $R^2 = 0.9962$ ) in a physiologically relevant range, with a detection limit of  $\sim 5$   $\mu\text{M}$  (Figures 2A and S2 (SI)).

The changes in FRET could be monitored in real-time (Figures 2B and S3 (SI)), and cleavage of the ACPP was further confirmed by SDS-polyacrylamide gel electrophoresis (PAGE) (Figure 2C) and by high-performance liquid chromatography mass spectrometry (HPLC-MS) (Figure S4 (SI)). To verify that the observed FRET change is not due to nonspecific peptide cleavage or damage to the fluorophores, we synthesized ACPP 3 (Figure S1 and Scheme S4 (SI)), an uncleavable version of 1, in which the boronic acid-containing linker was replaced with a polyethylene glycol-6 (PEG<sub>6</sub>) molecule. No ratio change was observed when the uncleavable ACPP 3 ( $1$   $\mu\text{M}$ ) was incubated with  $\text{H}_2\text{O}_2$  ( $2$  mM) over a period of 60 min (Figure S3 (SI)).

The response of ACPP 1 to  $\text{H}_2\text{O}_2$  requires the occurrence of the following three consecutive steps: reaction of the boronic acid with  $\text{H}_2\text{O}_2$  to form a phenolate, 1,6-elimination and




**Figure 2.** Selective and concentration-dependent cleavage of ACPP 1 by  $\text{H}_2\text{O}_2$ . (A) Fold increase in fluorescein/Cy5 emission ratio (524/672 nm) after 20 min incubation of ACPP 1 ( $1$   $\mu\text{M}$ ) with indicated concentrations of  $\text{H}_2\text{O}_2$ . Error bars represent  $\pm$  standard deviation. \* $p < 0.05$ . (B) Time course fluorescence emission spectra of ACPP 1 ( $1$   $\mu\text{M}$ ) in the presence of  $\text{H}_2\text{O}_2$  ( $1$  mM). (C)  $\text{H}_2\text{O}_2$ -dependent cleavage of ACPP 1 ( $1$   $\mu\text{M}$ ) after 30 min incubation with  $1$  mM  $\text{H}_2\text{O}_2$ . (D) Fold increase in fluorescein/Cy5 emission ratio at indicated times of ACPP 1 ( $1$   $\mu\text{M}$ ) with indicated ROS or their donors ( $100$   $\mu\text{M}$ , catalase  $0.5$  mg/mL).

dissociation of the polypeptides from one another. The linear dependency of the FRET change on  $\text{H}_2\text{O}_2$  concentration suggests that the boronic acid oxidation is the rate-limiting step. We therefore explored the kinetics of this process by measuring its second-order rate constant ( $1$   $\mu\text{M}$  ACPP 1 and  $1$ ,  $2.5$ , and  $5$  mM  $\text{H}_2\text{O}_2$ , Figure S5 (SI)) to find  $k = 1.34 \pm 0.13$   $\text{M}^{-1} \text{s}^{-1}$ , in agreement with previously reported results.<sup>8</sup> We then evaluated the selectivity of the  $\text{H}_2\text{O}_2$ -ACPP to  $\text{H}_2\text{O}_2$  over other biologically relevant extracellular ROS. For this, ACPP 1 ( $1$   $\mu\text{M}$ ) was incubated with various ROS ( $100$   $\mu\text{M}$ ), and the FRET ratio change was monitored for 60 min. A time-dependent increase in the FRET ratio was observed when ACPP 1 was treated with  $\text{H}_2\text{O}_2$  ( $\sim 6$ -fold over 60 min). In contrast, other ROS, or  $\text{H}_2\text{O}_2$  in the presence of catalase, had little to no effect on the FRET ratio (Figure 2D). Taken together, these results establish that  $\text{H}_2\text{O}_2$ -ACPP selectively reacts with physiological levels of  $\text{H}_2\text{O}_2$  in a concentration-dependent manner, culminating in fragmentation of the ACPP and release of its CPP domain.

Next, we explored whether  $\text{H}_2\text{O}_2$ -ACPP could be used to detect  $\text{H}_2\text{O}_2$  in the cellular environment. Initial experiments in which ACPP 1 ( $1$   $\mu\text{M}$ ) was treated with exogenous  $\text{H}_2\text{O}_2$  ( $10\text{--}125$   $\mu\text{M}$ ) in the presence of HL-60 cells, a human promyelocytic leukemia cell line, demonstrated an increase in FRET ratio with linear dependency on the applied  $\text{H}_2\text{O}_2$  concentration (Figures 3A and S6 (SI),  $R^2 = 0.9947$ ).

We then tested the ACPP's ability to detect endogenous levels of  $\text{H}_2\text{O}_2$ . HL-60 cells express both membrane and cytoplasmic NADPH oxidase (NOX) subunits. Exposure of these cells to stimulants such as calcimycin, opsonized zymosan, or phorbol 12-myristate-13-acetate (PMA) triggers assembly of functional NOX on the cellular membrane and generation of superoxide,<sup>36</sup> which is converted to various ROS including  $\text{H}_2\text{O}_2$ .<sup>37</sup> NOX activity is the main source of ROS generation in the oxidative burst mechanism of immune cells. When HL-60




**Figure 3.** Detection of  $\text{H}_2\text{O}_2$  by ACPP 1 in cellular environment. (A) Fold increase in fluorescein/Cy5 emission ratio (524/672 nm) after 30 min of ACPP 1 ( $1 \mu\text{M}$ ) upon exogenous addition of  $\text{H}_2\text{O}_2$  at indicated concentration in the presence of HL-60 cells. Error bars represent  $\pm$  standard deviation. (B) Time course of fold increase in fluorescein/Cy5 emission ratio (524/672 nm) of ACPP 1 ( $1 \mu\text{M}$ ) incubated with HL-60 cells at the indicated conditions (catalase  $0.5 \text{ mg/mL}$ , PMA  $0.5 \mu\text{M}$ ). Error bars represent  $\pm$  standard deviation.  $*p < 1 \times 10^{-10}$ ,  $**p < 1 \times 10^{-4}$ .

cells were treated with ACPP 1 ( $1 \mu\text{M}$ ) and either stimulated with PMA ( $0.5 \mu\text{M}$ ) or not, a time-dependent increase in FRET ratio was observed in the stimulated cells (Figure 3B).

Using the FRET ratio change from the exogenous  $\text{H}_2\text{O}_2$  application experiment as a calibration curve (Figure S5 (SI)), we calculated that under the aforementioned conditions, PMA-stimulated HL-60 cells generate  $\text{H}_2\text{O}_2$  at a rate of  $0.98 \pm 0.05 \text{ nmol}/10^4 \text{ cells/h}$ , in agreement with previously reported measurements.<sup>35,38</sup> Conversely, addition of catalase ( $0.5 \text{ mg/mL}$ ) to PMA-stimulated cells completely suppressed the ratio change. Interestingly, nonstimulated HL-60 cells exhibited a slight, but statistically significant ( $p < 0.0001$ ), increase in ratio compared to catalase-treated cells, whether PMA-stimulated or not, suggesting that nonstimulated cells produce a basal level of  $\text{H}_2\text{O}_2$ . The rate of  $\text{H}_2\text{O}_2$  production by nonstimulated cells was calculated to be  $0.050 \pm 0.004 \text{ nmol}/10^4 \text{ cells/h}$ , about 20-fold lower than PMA-stimulated cells. These results demonstrate that  $\text{H}_2\text{O}_2$ -ACPP has sufficient sensitivity to detect endogenously produced  $\text{H}_2\text{O}_2$  in the cellular environment.

Finally, we investigated the potential of  $\text{H}_2\text{O}_2$ -ACPP to detect  $\text{H}_2\text{O}_2$  endogenously produced by activated macrophages and neutrophils, in a lipopolysaccharide (LPS) model of lung inflammation. For this, C57BL/6 mice were either treated (LPS) or not (control) with  $10 \mu\text{g}$  of LPS by intranasal (i.n.) administration for four consecutive days.<sup>39</sup> Recruitment of inflammatory cells to the airways of mice treated with LPS was confirmed by hematoxylin and eosin staining (Figure S7 (SI)). Mice were then administered ACPP 1 i.n. ( $10 \text{ nmol}$ ), and after 6 h, lungs were harvested, inflated, and imaged for the fluorescein/Cy5 emission ratio. Lungs of LPS-treated mice presented  $\sim 2$ -fold increase in fluorescein/Cy5 emission ratio compared to control (Figure 4A,B).

To test whether  $\text{H}_2\text{O}_2$  contributed to the observed increase in ratio, LPS-treated mice were given D-penicillamine (DPA,  $1 \mu\text{mol}$ ), a  $\text{H}_2\text{O}_2$  scavenger,<sup>40–42</sup> 5 min prior to ACPP 1 administration. In our *in vitro* studies, DPA completely



**Figure 4.** *In vivo* targeting of  $\text{H}_2\text{O}_2$  by ACPPs 1 and 2. (A) Representative ratiometric fluorescent images of fluorescein/Cy5 (ACPP 1) or Alexa488/594 (ACPP 2) emission ratios of mouse lungs in the indicated conditions treated with ACPP 1 ( $10 \text{ nmol}$ ) or ACPP 2 ( $5 \text{ nmol}$ ) for 6 h. Right: scales of appropriate emission ratios. (B) Mean change in ratios of images presented in (A) with additional animals ( $n = 5$ ). Error bars represent  $\pm$  standard deviation.  $*p < 0.05$ ,  $**p < 0.005$ . (C) SDS-PAGE analysis of lung extracts from LPS-mice treated with ACPPs 1–3 for 6 h. Bands were pseudocolored according to their emission spectra (Figure S9 (SI)): intact ACPP (purple) or cleaved ACPP (green).

inhibited the reaction between ACPP 1 and  $\text{H}_2\text{O}_2$  (Figure S8 (SI)). Lungs of LPS- and DPA-treated mice showed a decreased fluorescein/Cy5 emission ratio, at least as low as control mouse lungs. Cleavage of ACPP 1 in lungs of LPS-treated mice was confirmed by SDS-PAGE analysis of homogenized lung extracts (Figure 4C). In contrast, when similar mice were treated with uncleavable ACPP 3, no cleavage products were observed. We repeated the experiments described above with ACPP 2. Results were consistent with those observed with ACPP 1; i.e., lungs of LPS-treated mice showed  $\sim 2$ -fold increase in ratio (Alexa488/Alexa594 emission) that was completely suppressed by DPA (Figure 4A–C), suggesting that  $\text{H}_2\text{O}_2$ -ACPP is a platform that can accommodate a range of fluorophores. Taken together, these results suggest that  $\text{H}_2\text{O}_2$ -ACPP can target and respond to endogenous levels of  $\text{H}_2\text{O}_2$  produced in a model of lung inflammation *in vivo*.

In conclusion, we developed a  $\text{H}_2\text{O}_2$  targeting mechanism based on activatable cell-penetrating peptides ( $\text{H}_2\text{O}_2$ -ACPP). Fluorescence labeling of the  $\text{H}_2\text{O}_2$ -ACPP enabled visualization of its reaction with  $\text{H}_2\text{O}_2$  through FRET disruption. The  $\text{H}_2\text{O}_2$ -ACPP reacts selectively and in a concentration-dependent manner with  $\text{H}_2\text{O}_2$  to release its CPP domain, whose adhesiveness and nondiffusibility preserve spatial resolution. Its low micromolar sensitivity enabled detection and quantification of  $\text{H}_2\text{O}_2$  secreted by activated HL-60 cells. Moreover,  $\text{H}_2\text{O}_2$ -ACPP was sensitive enough to react with endogenous levels of  $\text{H}_2\text{O}_2$  in an *in vivo* model of lung inflammation. Developing ACPPs for  $\text{H}_2\text{O}_2$  targeting will potentially enable its imaging by a variety of modalities,

including fluorescence, magnetic resonance, and radioactive techniques. Importantly, a similar targeting mechanism could be further used for directed delivery of therapeutics to local sites of oxidative stress related diseases.

## ■ ASSOCIATED CONTENT

### 📄 Supporting Information

Experimental details, synthetic procedures, characterization methods, molecules structures, and figures. This material is available free of charge via the Internet at <http://pubs.acs.org>.

## ■ AUTHOR INFORMATION

### Corresponding Author

rtsien@ucsd.edu

### Notes

The authors declare the following competing financial interest(s): R. Y. Tsien is a scientific advisor to Avelas Biosciences, which has licensed the ACPD technology from University of California Regents. All the other authors declare no competing financial interests.

## ■ ACKNOWLEDGMENTS

The authors thank Qing Xiong and Larry Gross for technical assistance and to all other lab members for helpful discussions. This work was supported by the Howard Hughes Medical Institute, National Institute of Health (NIH) Grant 5R01CA158448-02 and Department of Defense (DoD) Grant W81XWH-09-1-0699 (to R.Y.T.), NIH Training Grant 5R25CA153915-03 (to R.W. and C.N.F.), American Asthma Foundation Grant 11-0321 and NIH 1F30HL118998-01 (to C.N.F.).

## ■ REFERENCES

- (1) D'Autreaux, B.; Toledano, M. B. *Nat. Rev. Mol. Cell Biol.* **2007**, *8*, 813.
- (2) Veal, E. A.; Day, A. M.; Morgan, B. A. *Mol. Cell* **2007**, *26*, 1.
- (3) Houstis, N.; Rosen, E. D.; Lander, E. S. *Nature* **2006**, *440*, 944.
- (4) Touyz, R. M.; Schiffrin, E. L. *Histochem. Cell Biol.* **2004**, *122*, 339.
- (5) Cai, H. *Cardiovasc. Res.* **2005**, *68*, 26.
- (6) Barnham, K. J.; Masters, C. L.; Bush, A. I. *Nat. Rev. Drug Discovery* **2004**, *3*, 205.
- (7) Reuter, S.; Gupta, S. C.; Chaturvedi, M. M.; Aggarwal, B. B. *Free Radical Biol. Med.* **2010**, *49*, 1603.
- (8) Van de Bittner, G. C.; Dubikovskaya, E. A.; Bertozzi, C. R.; Chang, C. J. *Proc. Natl. Acad. Sci. U. S. A.* **2010**, *107*, 21316.
- (9) Van de Bittner, G. C.; Bertozzi, C. R.; Chang, C. J. *J. Am. Chem. Soc.* **2013**, *135*, 1783.
- (10) Lee, D.; Khaja, S.; Velasquez-Castano, J. C.; Dasari, M.; Sun, C.; Petros, J.; Taylor, W. R.; Murthy, N. *Nat. Mater.* **2007**, *6*, 765.
- (11) Karton-Lifshin, N.; Segal, E.; Omer, L.; Portnoy, M.; Satchi-Fainaro, R.; Shabat, D. *J. Am. Chem. Soc.* **2011**, *133*, 10960.
- (12) de Gracia Lux, C.; Joshi-Barr, S.; Nguyen, T.; Mahmoud, E.; Schopf, E.; Fomina, N.; Almutairi, A. *J. Am. Chem. Soc.* **2012**, *134*, 15758.
- (13) Liu, J.; Pang, Y.; Zhu, Z.; Wang, D.; Li, C.; Huang, W.; Zhu, X.; Yan, D. *Biomacromolecules* **2013**, *14*, 1627.
- (14) Kuang, Y.; Balakrishnan, K.; Gandhi, V.; Peng, X. *J. Am. Chem. Soc.* **2011**, *133*, 19278.
- (15) Jiang, T.; Olson, E. S.; Nguyen, Q. T.; Roy, M.; Jennings, P. A.; Tsien, R. Y. *Proc. Natl. Acad. Sci. U. S. A.* **2004**, *101*, 17867.
- (16) Olson, E. S.; Jiang, T.; Aguilera, T. A.; Nguyen, Q. T.; Ellies, L. G.; Scadeng, M.; Tsien, R. Y. *Proc. Natl. Acad. Sci. U. S. A.* **2010**, *107*, 4311.
- (17) Whitney, M.; Crisp, J. L.; Olson, E. S.; Aguilera, T. A.; Gross, L. A.; Ellies, L. G.; Tsien, R. Y. *J. Biol. Chem.* **2010**, *285*, 22532.

- (18) Whitney, M.; Savariar, E. N.; Friedman, B.; Levin, R. A.; Crisp, J. L.; Glasgow, H. L.; Lefkowitz, R.; Adams, S. R.; Steinbach, P.; Nashi, N.; Nguyen, Q. T.; Tsien, R. Y. *Angew. Chem., Int. Ed. Engl.* **2013**, *52*, 325.
- (19) Ainley, A. D.; Challenger, F. *J. Chem. Soc.* **1930**, 2171.
- (20) Kuivila, H. G. *J. Am. Chem. Soc.* **1954**, *76*, 870.
- (21) Kuivila, H. G.; Armour, A. G. *J. Am. Chem. Soc.* **1957**, *79*, 5659.
- (22) Chang, M. C. Y.; Pralle, A.; Isacoff, E. Y.; Chang, C. J. *J. Am. Chem. Soc.* **2004**, *126*, 15392.
- (23) Lippert, A. R.; De Bittner, G. C. V.; Chang, C. J. *Acc. Chem. Res.* **2011**, *44*, 793.
- (24) Savariar, E. N.; Felsen, C. N.; Nashi, N.; Jiang, T.; Ellies, L. G.; Steinbach, P.; Tsien, R. Y.; Nguyen, Q. T. *Cancer Res.* **2013**, *73*, 855.
- (25) Antunes, F.; Cadenas, E. *FEBS Lett.* **2000**, *475*, 121.
- (26) Seaver, L. C.; Imlay, J. A. *J. Bacteriol.* **2001**, *183*, 7182.
- (27) Lennon, S. V.; Martin, S. J.; Cotter, T. G. *Cell Proliferation* **1991**, *24*, 203.
- (28) Antunes, F.; Cadenas, E. *Free Radical Biol. Med.* **2001**, *30*, 1008.
- (29) Kulagina, N. V.; Michael, A. C. *Anal. Chem.* **2003**, *75*, 4875.
- (30) Behl, C.; Davis, J. B.; Lesley, R.; Schubert, D. *Cell* **1994**, *77*, 817.
- (31) Hyslop, P. A.; Zhang, Z.; Pearson, D. V.; Phebus, L. A. *Brain Res.* **1995**, *671*, 181.
- (32) Horoz, M.; Bolukbas, C.; Bolukbas, F. F.; Aslan, M.; Koylu, A. O.; Selek, S.; Erel, O. *BMC Infect. Dis.* **2006**, *6*, 114.
- (33) Sznajder, J. I.; Fraiman, A.; Hall, J. B.; Sanders, W.; Schmidt, G.; Crawford, G.; Nahum, A.; Factor, P.; Wood, L. D. *Chest* **1989**, *96*, 606.
- (34) Suematsu, M.; Schmid-Schonbein, G. W.; Chavez-Chavez, R. H.; Yee, T. T.; Tamatani, T.; Miyasaka, M.; Delano, F. A.; Zweifach, B. W. *Am. J. Physiol.* **1993**, *264*, H881.
- (35) Szatrowski, T. P.; Nathan, C. F. *Cancer Res.* **1991**, *51*, 794.
- (36) Teufelhofer, O.; Weiss, R. M.; Parzefall, W.; Schulte-Hermann, R.; Micksche, M.; Berger, W.; Elbling, L. *Toxicol. Sci.* **2003**, *76*, 376.
- (37) Babior, B. M. *Blood* **1999**, *93*, 1464.
- (38) Test, S. T.; Weiss, S. J. *J. Biol. Chem.* **1984**, *259*, 399.
- (39) Starkhammar, M.; Kumlien Georen, S.; Swedin, L.; Dahlen, S. E.; Adner, M.; Cardell, L. O. *PLoS One* **2012**, *7*, e32110.
- (40) Winterbourn, C. C.; Metodiewa, D. *Free Radical Biol. Med.* **1999**, *27*, 322.
- (41) Ledson, M. J.; Bucknall, R. C.; Edwards, S. W. *Ann. Rheum. Dis.* **1992**, *51*, 321.
- (42) Sanderud, J.; Oroszlan, G.; Bjoro, K.; Kumlin, M.; Saugstad, O. D. *J. Perinat. Med.* **1995**, *23*, 385.